ENSC
Ensysce Biosciences, Inc. Common Stock
Nasdaq · usd
Ensysce Biosciences, Inc. Common Stock (ENSC) trades at $0.3600 (-0.17%) as of 7:50:07 PM EST on Nov 20, 2026, -29.55% over the past month. Market cap is $7M, with 1.0 days to cover in short interest.
Stock performance
How Ensysce Biosciences, Inc. Common Stock (ENSC) stock has performed from one day to one year, with its 52-week range.
- 1D
- -0.17%
- 1W
- -13.96%
- 1M
- -29.55%
- YTD
- -60.87%
- 1Y
- -78.44%
- 52-wk range
- $0.23 – $1.85
Key statistics
Today's trading snapshot for ENSC: day range, open, previous close, volume and market cap.
- Day range
- $0.36 – $0.37
- Open
- $0.36
- Prev close
- $0.36
- Volume
- 83.39K
- Market cap
- $7M
- Shares out
- 19.46M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Ensysce Biosciences, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 1.13
- P/B
- 0.26
- P/FCF
- —
- ROE
- -332.4%
- ROA
- -294.7%
- Debt/Equity
- 0.01
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events Ensysce Biosciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Executive officer appointmentNov 4, 2026
“Dr. Lynn Kirkpatrick ... agreed that she would assume the title of Chief Operating Officer of the Company immediately following the Annual Meeting.”
- Preferred stock modificationSep 29, 2026
On September 25, 2026, the Company amended the Series C Certificate of Designation to remove Section 6.5.3 and other references to Section 6.5.3 in the Series C Certificate of Designation (the “Amendment”). Section 6.5.3 provides that the Series C Preferred Stock is redeemable for cash at the option of the holder thereof under specified circumstances. The Amendment was effective upon filing.
- Listing deficiency noticeAug 25, 2026
On August 25, 2026, Nasdaq granted the Company an additional 180 calendar days, or until February 22, 2027, to regain compliance with the Minimum Price Listing Requirement.
- Private placementAug 24, 2026
Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 120,260 shares of its Series C Preferred Stock for an aggregate purchase price of approximately $43 million (the "Financing") to be purchased in two tranches. At the closing of the first tranche of the Financing (the "Initial Closing") that occurred on August 7, 2026, the Company raised more than $21 million in gross proceeds.
- Executive officer appointmentAug 6, 2026
Pursuant to the Merger Agreement, on August 4, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing and appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.
Dividend history and stock splits
Ensysce Biosciences, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-15Dec 6, 2024
- 1-for-12Mar 31, 2023
- 1-for-20Oct 28, 2022
ENSC short interest
How heavily ENSC is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.0
- Short interest
- 88.61K
- Avg volume
- 264.79K
As of · reported to FINRA twice monthly.
ENSC news
The latest news and headlines about Ensysce Biosciences, Inc. Common Stock (ENSC).
- Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic ReviewpositiveBenzinga· Feb 27, 2026
- Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet StrengthpositiveGlobeNewswire Inc.· Feb 27, 2026
- Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsightpositiveGlobeNewswire Inc.· Jan 28, 2026
- Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)positiveGlobeNewswire Inc.· Aug 15, 2025
- Ensysce Biosciences Narrows Loss in Q2neutralThe Motley Fool· Aug 13, 2025
Frequently asked questions
What is the Ensysce Biosciences, Inc. Common Stock (ENSC) stock price today?
Ensysce Biosciences, Inc. Common Stock (ENSC) is trading at $0.3600 (-0.17% on the day) as of 7:50:07 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Ensysce Biosciences, Inc. Common Stock?
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses.
What is the short interest in ENSC?
As of Oct 30, 2026, ENSC has 88.61K shares short and 1.0 days to cover.
What exchange is ENSC listed on?
Ensysce Biosciences, Inc. Common Stock (ENSC) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ENSC with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ENSC analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.